OakChart

Satellos Bioscience Inc

MSLEHealthcare·Biotechnology·Canada·Micro·NASD·Nov 11 • 11:29 AM ET

6.99+0.04 (0.58%)
2026-11-11 17:29 CET
Market cap
147.45 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-34.61 USD m
Free cash flow, TTM
-28.76 USD m
EPS diluted, TTM
-1.98
P/E
-
Compare

Price

MSLE against its 20, 50 and 200-day averages
2050200beat
6.008.0010.00241K482KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MSLEclose 6.9920-day 6.7150-day 7.87200-day 8.386.9952w low

47.8% under the 52-week high of 13.40 on 3 Mar 2026. 52-week low 5.30 on 14 Nov 2025. Last 15 sessions, 24.4% high to low

Profile

MSLE
52-week range, 21% of the way up
5.3013.39

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX and Leveraging MyoReGenX, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Employees18
IPOFeb 19, 2009
Beta1.61
ATR, 14d0.53
Rel volume0.24
Short float0.83%
Insider own27.85%
Inst own28.74%

Snapshot

6 groups

Valuation

Index-
Market Cap148.33M
Enterprise Value86.49M
Income-34.61M
Sales0.00M
Book/sh2.87
Cash/sh2.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees18
IPOFeb 19, 2009

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.43
P/C2.40
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.22
Current Ratio11.22
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.98
EPS next Y-2.41
EPS next Q-0.60
EPS this Y-38.90%
EPS next Y-2.06%
EPS next 5Y-12.18%
EPS past 3/5Y16.48% 36.03%
Sales past 3/5Y- -
EPS Y/Y TTM-6.71%
Sales Y/Y TTM-
EPS Q/Q-43.13%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-8.53% -

Ownership

Insider Own27.85%
Insider Trans0.00%
Inst Own28.74%
Inst Trans-0.12%
ROA-64.76%
ROE-70.45%
ROIC-57.77%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.23%
SMA50-11.15%
SMA200-16.61%
Trades-

Technical

Shs Outstand20.84M
Shs Float15.31M
Short Float0.83%
Short Ratio2.75
Short Interest0.13M
52W High13.39 -47.82%
52W Low5.30 31.82%
Volatility8.98% 8.12%
ATR (14)0.53
RSI (14)48.43
Beta1.61
Rel Volume0.24
Avg Volume46.28K
Volume3,706

Performance

Perf Week8.04%
Perf Month-0.71%
Perf Quarter-28.82%
Perf Half Y-3.98%
Perf YTD18.88%
Perf Year13.68%
Perf 3Y164.22%
Perf 5Y-48.31%
Perf 10Y-2.92%
Recom1.00
Target Price22.09
Prev Close6.95
Price6.99
Change %0.58%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Apr 28, 2026InitiatedGGuggenheimBuy$23+229.0%
Apr 06, 2026InitiatedLLeerink PartnersOutperform$20+186.1%
Mar 11, 2026InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
EWTXEdgewise Therapeutics Inc5.15B
CAPRCapricor Therapeutics Inc582.54M
SLDBSolid Biosciences Inc866.66M
PEPGPepGen Inc391.67M
TRDAEntrada Therapeutics Inc206.32M
SRPTSarepta Therapeutics Inc1.76B
DYNDyne Therapeutics Inc3.42B
RGNXRegenxbio Inc557.03M
WVEWave Life Sciences Inc675.51M
SRRKScholar Rock Holding Corp5.78B

News

latest 14 of 70
  • Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback (GlobeNewswire) +13.23%
  • Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study (GlobeNewswire)
  • Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience (GlobeNewswire) +5.20%
  • Satellos to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Satellos Granted Composition of Matter Patent for Forazapadin (GlobeNewswire) -5.29%
  • Loading…
  • Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy (GlobeNewswire)
  • Satellos Receives FDA Clearance to Study Forazapadin in FSHD (InvestorsHub)
  • Satellos stock jumps after FDA clears FSHD trial for forazapadin (Investing.com)
  • Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development (GlobeNewswire)
  • Satellos to Present at the 31st Annual Congress of the World Muscle Society (GlobeNewswire)
  • Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 (GlobeNewswire) +9.15%
  • Satellos to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Satellos Bioscience: Q2 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.560-0.516-0.5600.000.006
2026Q12026-05-15-0.530-0.490-0.5300.000.005
2025Q42026-03-27-0.500-0.377-0.4720.000.003
2025Q32025-11-14-0.360-0.328-0.4180.000.002
2026Q3---0.603--0.008
2026Q4---0.641--0.008
2027Q1---0.608--0.006
2027Q2---0.620--0.006
2027Q3---0.669--0.006
2027Q4---0.815--0.006
2028Q1---0.590---1
2028Q2---0.540---1
2028Q3---0.550---1
2028Q4---0.630---1
2029Q1---0.640---1
2029Q2---0.720---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-2.104-1.923-2.1440.000.00
2025FY-1.700-1.300-1.6900.000.00
2026FY--2.361--0.00
2027FY--2.410--0.00
2028FY--2.400--20.33
2029FY--1.625--50.08
2030FY--0.422--81.43

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-155000.000.000.00
2026Q3S2026-10-076000.000.000.00
2026Q3S2026-08-145000.000.000.00
2026Q3S2026-08-135000.000.000.00
2026Q3S2026-05-155000.000.000.00
2026Q3S2026-04-024000.000.000.00
2026Q3S2026-03-273000.000.000.00
2026Q3S2026-03-102000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00

Estimate history

EPS, annual-1.849-3.733-2.863-15.907-6.164-2.925-1.635-2.144-1.704-1.9823
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.469-0.704-0.316-0.444-0.393-0.418-0.472-0.53-0.563
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.3520.3520.6410.0762.753.4839.39913.81815.45920.838
Period201720182019202020212022202320242025MRQ
Shares, quarterly9.4039.44813.81813.81914.69215.42415.45920.83120.838
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.260.130.000.000.00
Gross Profit-0.01-0.01-0.01-0.01-0.26-0.13-0.00-0.00-0.00
Selling, General and Administrative Excl. Other35.8226.4520.2811.456.203.741.441.661.70
Research and Development26.3918.4314.316.531.991.500.670.691.10
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-35.82-26.46-20.30-11.46-6.46-3.87-1.44-1.66-1.70
Interest Expense0.000.000.000.130.000.790.020.000.00
Unusual Expense0.000.002.890.322.227.76-0.07-0.00
Net Income Before Taxes-34.46-24.70-20.51-11.77-8.68-12.40-1.38-1.66-1.31
Income Taxes0.150.170.000.000.02-0.03-0.20-0.200.00
Consolidated Net Income-34.61-24.87-20.51-11.77-8.70-12.37-1.18-1.46-1.31
Net Income From Continuing Operations-34.61-24.87-20.51-11.77-8.70-12.37-1.18-1.46-1.31
Net Income-34.61-24.87-20.51-11.77-8.70-12.37-1.18-1.46-1.31
EPS (Recurring)-1.66-1.70-1.93-1.60-2.40-3.46-16.62-2.86-3.73
EPS (Basic, Before Extraordinaries)-1.98-1.70-2.14-1.64-2.92-6.16-15.91-2.86-3.73
EPS (Diluted)-1.98-1.70-2.14-1.64-2.92-6.16-15.91-2.86-3.73
EBITDA-35.82-26.45-20.28-11.45-6.20-3.74-1.44-1.66-1.70
Non-Operating Income (Expense)1.371.762.680.13-0.000.010.000.000.39
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.502.381.541.610.810.770.070.000.00
Shares Outstanding20.8415.4613.829.403.482.750.080.640.35
Market Capitalization147.45147.4597.8336.667.1726.737.508.072.69

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.010.00
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.00-0.01-0.00
Selling, General and Administrative Excl. Other12.1610.047.655.966.376.485.583.71
Research and Development9.647.315.463.994.444.543.962.39
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.16-10.04-7.65-5.97-6.37-6.48-5.59-3.71
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.002.90
Net Income Before Taxes-11.67-9.74-7.25-5.80-5.58-6.08-4.37-6.63
Income Taxes0.040.030.060.020.030.060.000.00
Consolidated Net Income-11.72-9.77-7.30-5.82-5.61-6.14-4.37-6.63
Net Income From Continuing Operations-11.72-9.77-7.30-5.82-5.61-6.14-4.37-6.63
Net Income-11.72-9.77-7.30-5.82-5.61-6.14-4.37-6.63
EPS (Recurring)-0.56-0.53-0.47-0.42-0.39-0.44-0.32-0.49
EPS (Basic, Before Extraordinaries)-0.56-0.53-0.47-0.42-0.39-0.44-0.32-0.70
EPS (Diluted)-0.56-0.53-0.47-0.42-0.39-0.44-0.32-0.70
EBITDA-12.16-10.04-7.65-5.96-6.37-6.48-5.58-3.71
Non-Operating Income (Expense)0.490.310.400.160.790.401.22-0.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.680.530.720.570.610.460.320.17
Shares Outstanding20.8420.8315.4615.4214.6913.8213.829.45
Market Capitalization147.4587.0390.9093.6386.3993.7697.8337.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments27.7148.5730.021.423.860.560.760.010.90
Short Term Receivables0.370.440.440.190.420.320.320.100.07
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.801.760.120.040.030.000.040.030.13
Total Current Assets31.8850.7730.581.654.310.891.130.131.10
Net Property, Plant & Equipment0.010.000.010.010.010.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.002.972.895.650.000.000.000.00
Other Assets0.000.000.030.030.000.000.000.000.00
Total Assets31.8950.7733.594.579.960.891.130.131.10
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.000.000.000.00
Income Tax Payable0.07--------
Other Current Liabilities4.033.582.752.091.670.170.620.590.23
Total Current Liabilities4.113.582.752.091.670.170.620.590.23
Long Term Debt0.000.000.000.000.000.860.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00-0.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities4.113.582.752.091.671.030.620.590.23
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity27.7847.1930.852.498.30-0.140.51-0.460.87
Total Shareholders Equity27.7847.1930.852.498.30-0.140.51-0.460.87
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity27.7847.1930.852.498.30-0.140.51-0.460.87
Total Liabilities & Stockholders Equity31.8950.7733.594.579.960.891.130.131.10
Book Value Per Share1.803.413.280.713.02-1.900.80-1.302.47
Tangible Book Value Per Share1.803.412.97-0.120.96-1.900.80-1.302.47
Full-Time Employees181412------
Price to Book Ratio2.422.071.071.203.22-12.7415.84-5.872.44
Return on Assets-60.18-48.62-61.68-119.64-238.00-116.59-231.36-213.89-65.15
Return on Equity-66.36-52.57-70.64-161.29-320.84-644.55-5,593.42-640.01-73.52
Return on Invested Capital-89.52-43.47-38.16-349.83-149.04-164.86-286.71--109.85
Quick Ratio7.7714.1611.130.792.595.131.810.224.77
Current Ratio7.7714.1611.130.792.595.131.810.224.77

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-34.36-24.87-20.51-11.77-8.70-12.37-1.18-1.46-1.31
Depreciation0.000.000.010.010.260.130.000.000.00
Other Funds (Non Cash)3.492.753.010.813.298.610.080.000.00
Funds from Operations-30.86-22.12-17.48-10.96-5.15-3.63-1.10-1.46-1.31
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.11-1.48-0.750.270.76-0.39-0.14-0.230.46
Cash from Operating Activities-28.75-23.60-18.23-10.68-4.39-4.01-1.24-1.69-0.85
Capital Expenditures-0.01-0.01-0.00-0.01-0.00-0.010.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.001.390.000.00-
Purchase or Sale of Investments-54.56-9.414.63-12.980.000.000.000.000.00
Purchase of Investments-74.29-23.37-27.25-12.980.000.000.000.000.00
Sale Or Maturity of Investments19.7313.9631.880.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-54.56-9.424.63-12.99-0.001.390.00-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock52.522.2439.0437.642.135.790.662.420.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock52.522.2439.0437.642.135.790.662.420.00
Proceedsfrom Stock Options47.030.0031.2424.052.135.650.662.420.00
Issuance or Reduction of Debt, Net0.000.000.00-0.210.000.150.810.000.00
Change in Long Term Debt0.000.000.00-0.210.000.150.810.000.00
Issuance of Long Term Debt0.000.000.001.660.000.150.810.000.00
Reduction of Long Term Debt0.000.000.00-1.870.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.320.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities52.522.2439.0437.752.135.941.472.420.00
Exchange Rate Effect-0.050.500.540.85-0.00-0.000.000.00-0.01
Net Change in Cash-30.84-30.2725.9814.92-2.263.310.240.74-0.86
Free Cash Flow-28.76-23.60-18.23-10.70-4.39-4.02-1.24-1.69-0.85
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments61.8469.9127.7134.6138.2241.19
Short Term Receivables0.780.730.370.200.190.34
Inventories0.000.000.000.000.000.00
Other Current Assets3.144.583.802.682.712.84
Total Current Assets65.7675.2231.8837.5041.1144.37
Net Property, Plant & Equipment0.010.010.010.010.010.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets65.7775.2331.8937.5041.1244.37
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.00
Income Tax Payable0.030.100.070.110.100.06
Other Current Liabilities5.834.464.033.392.672.64
Total Current Liabilities5.864.564.113.502.772.70
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.864.564.113.502.772.70
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity59.9170.6627.7834.0038.3541.67
Total Shareholders Equity59.9170.6627.7834.0038.3541.67
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity59.9170.6627.7834.0038.3541.67
Total Liabilities & Stockholders Equity65.7775.2331.8937.5041.1244.37
Book Value Per Share2.873.391.802.202.613.02
Tangible Book Value Per Share2.873.391.802.202.613.02
Full-Time Employees--18---
Price to Book Ratio2.423.133.272.752.252.25
Return on Assets-64.76-47.66-60.18-79.16-69.60-59.34
Return on Equity-70.45-50.74-66.36-89.10-76.26-64.18
Return on Invested Capital-19.56-13.82-26.28-17.12-14.62-14.74
Quick Ratio11.2216.487.7710.7014.8416.44
Current Ratio11.2216.487.7710.7014.8416.44

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-11.62-9.77-7.09-5.88-5.82-6.14
Depreciation0.000.00-0.000.000.000.00
Other Funds (Non Cash)0.940.890.750.900.470.64
Funds from Operations-10.68-8.88-6.33-4.98-5.35-5.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.73-0.71-0.730.820.29-1.87
Cash from Operating Activities-7.95-9.59-7.06-4.16-5.06-7.37
Capital Expenditures0.00-0.000.00-0.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-3.17-33.33-2.47-15.588.620.00
Purchase of Investments-6.99-43.88-7.85-15.560.000.00
Sale Or Maturity of Investments3.8210.555.38-0.028.620.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-3.17-33.34-2.47-15.598.620.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.2051.900.120.711.420.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.2051.900.120.711.420.00
Proceedsfrom Stock Options-0.2247.250.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.2051.900.120.711.420.00
Exchange Rate Effect0.03-0.090.17-0.160.490.00
Net Change in Cash-11.298.89-9.24-19.205.47-7.36
Free Cash Flow-7.95-9.59-7.06-4.16-5.06-7.37

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.83%0.1M15.3M41.96K
2026-10-150.64%0.1M15.3M48.24K
2026-09-300.69%0.1M15.3M57.83K
2026-09-150.54%0.1M15.3M53.81K
2026-08-310.59%0.1M15.2M54.16K
2026-08-140.61%0.1M15.0M55.69K
2026-07-310.77%0.1M14.8M56.52K
2026-07-150.70%0.1M14.8M53.26K
2026-06-300.56%0.1M14.8M46.07K
2026-06-150.47%0.1M14.8M61.75K
2026-05-290.52%0.1M14.8M73.64K
2026-05-150.57%0.1M14.8M77.64K
2026-04-300.55%0.1M17.3M82.52K
2026-04-150.46%0.1M17.3M78.29K
2026-03-310.40%0.1M17.4M68.36K
2026-03-130.53%0.1M12.9M43.23K
2026-02-270.10%0.0M12.9M27.15K
2026-02-130.05%0.0M12.9M20.88K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-06SEC
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-08-14SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-11F-XFor appointment of agent for service of process by issuers registering securities (if filed on Form F-8, F-9, F-10 or F-80, or registering securities or filing periodic reports on Form 40-F, or by any person filing certain tender offer documents, or by anSEC
2026-08-11F-10Registration statement for securities of certain Canadian issuers under the Securities Act of 1933SEC
2026-07-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-08SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC
2026-05-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-19SEC
2026-05-15SCHEDULE 13GSEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-12SCHEDULE 13GSEC
2026-04-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-09SEC
2026-03-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-27SEC
2026-03-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-2740-FRegistration Statement Pursuant to Section 12 of the Securities Exchange Act of 1934 or Annual Report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 19342025-12-31SEC
2026-03-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FRANKLIN RESOURCES INC4.51%
Siren, L.L.C.4.28%
Vivo Capital, LLC3.91%
Point72 Asset Management, L.P.3.28%
SPHERA FUNDS MANAGEMENT LTD.3.13%
Woodline Partners LP2.40%
Stonepine Capital Management, LLC2.36%
MONTANOVA CAPITAL, LLC2.28%
Avidity Partners Management LP1.86%
Saturn V Capital Management LP1.68%

Funds

Fund% owned
Franklin Biotechnology Discovery Fund1.18%
Fidelity Nasdaq Composite Index Fund0.06%

OakChart. MSLE. Cached 15 minutes.

Some panels did not load: insider.